Largest clinical trial for potential new psoriasis treatment

Novartis Pharmaceuticals UK has announced the launch of the UK's largest clinical trial to investigate a potential new biologic treatment for adults with moderate-severe psoriasis.

Dr Richard Warren, Senior Lecturer, University of Manchester and Honorary Consultant Dermatologist at Salford Royal NHS Foundation Trust and Lead Investigator for the clinical trial, said: "Psoriasis is a common life ruining condition with effects on patients' quality of life similar to diseases such as cancer, , arthritis and depression. This clinical trial will investigate a new biological therapy for the treatment of psoriasis in what will be the largest trial of its type in the UK to date."

The trial is designed to provide more information about this potential new treatment for moderate-severe psoriasis and will involve approximately 50 dermatology centres across the UK. Adults in the UK with psoriasis who have received treatment from a dermatologist can find out more about the clinical trial at

Bernadette, a 46 year old woman has been living with psoriasis since she was a child, said: "I was diagnosed with psoriasis at the age of 12. From that day my life changed for the worse. I hid my arms and legs as I was scared of what people would think. My confidence was shattered. My first marriage broke down due to heavy drinking and suicide attempts, I felt worthless. Psoriasis has affected me physically and mentally everyday."

Psoriasis may profoundly affect all aspects of person's social and personal lives as well as their work.

  • There is no cure for psoriasis and over 70% of psoriasis patients report only low to moderate satisfaction with currently available treatment options2
  • More than 5% of people with psoriasis experience depression and suicidal thoughts
  • Up to 32% of people with moderate to severe psoriasis have been found to have problems with alcohol
  • 20% of people with severe psoriasis take antidepressant medication

Psoriasis is a chronic inflammatory condition which is estimated to affect between 2% and 3% of the UK population – up to 1.8 million people. Plaque psoriasis is the most common type of psoriasis, accounting for 80% of cases and is characterised by thick and extensive skin lesions, known to cause itching, scaling and pain. More than one third of people with plaque psoriasis suffer from moderate-severe psoriasis, which can be difficult to treat. People are considered to have moderate-severe when more than 10% of their body surface is affected, or when sensitive areas of the body are involved, such as hands or feet, which impacts on a person's quality of life.

add to favorites email to friend print save as pdf

Related Stories

Skin care tips for psoriasis patients

Aug 25, 2013

(HealthDay)—Sun protection is among the skin care habits that can help people with the chronic skin condition psoriasis reduce some of the discomfort they may experience, such as skin itching, cracking ...

Psoriasis patients should be screened for CVD

Oct 29, 2013

World Psoriasis Day is held today with the theme "Global access to treatment" to highlight the fact that more than 125 million people have psoriasis but not all have access to treatment. Early and effective therapy lessens ...

Recommended for you

US orders farms to report pig virus infections

Apr 18, 2014

The U.S. government is starting a new program to help monitor and possibly control the spread of a virus that has killed millions of pigs since showing up in the country last year.

Foreigner dies of MERS in Saudi

Apr 18, 2014

A foreigner has died after she contracted MERS in the Saudi capital, the health ministry said on announced Friday, bringing the nationwide death toll to 73.

Vietnam battles fatal measles outbreak

Apr 18, 2014

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

New clues on tissue scarring in scleroderma

Apr 18, 2014

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

User comments